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Abstract
Introduction: Diastolic dysfunction (DD) and cardiac dyssynchrony (DS) are involved in the progression of chronic 
heart failure (CHF). A comparative analysis was conducted of the effect of a 6-month course of nebivolol and bisopr-
olol on DD, DS and metalloproteinase-9 (MMP-9) level in patients with ischemic chronic heart failure with preserved 
ejection fraction (HFpEF) and with midrange ejection fraction (HFmrEF), as well as in patients with comorbid type 2 
diabetes mellitus (T2DM) in the setting of coronary artery bypass grafting (CABG) after 6 months of therapy.
Materials and methods: The study included 308 patients with CHF FC I-II, left ventricular ejection fraction (LVEF) 
>40%, who had undergone CABG. The average dose of nebivolol in patients with DS 6 months later was 5.1±2.6 mg/
day, and bisoprolol – 4.9±2.4 mg/day. Echocardiography (EchoCG) and evaluation of MMP-9 in blood plasma were 
performed. Mechanical myocardial asynchrony was determined by calculating the standard deviation of time to peak 
systolic myocardial velocity (TS-SD) and maximum segment delay (TS12) using a 6-basal and-midsegment model.
Results and discussion: MMP-9 level in patients with CHF before CABG was 4.7 times higher (p<0.001). MMP-9 
correlated with LVEF (r=-0.60, p<0.001), E/A (r=-0.49, p<0.001), DT (r=0.43, p<0.001), E` (r=-0.58, p<0.001) and 
DS: TS12 (r=0.54, p<0.001), TS-SD (r=0.49, p<0.001). The six-month course of nebivolol improved the values of DS: 
TS12 – by 30% (p<0.001), TS-SD – by 32% (p<0.01) and reduced the MMP-9 level by 11% (p<0.001). In patients 
with HFmrEF without DS nebivolol increased E/A by 19% (p<0.01), E` – by 16% (P<0.05), and decreased E/E’ by 9% 
(p<0.05), DT – by 12% (p<0.05). In patients with HFpEF and DM2, nebivolol reduced TS12 by 37% (p<0.01), TS-SD 
– by 29% (p<0.05) and MMP-9 – by 13% (p<0.05).
Conclusion: The positive effect of nebivolol on the DS, DD of the LV in patients with HFpEF, HFmrEF and with 
comorbid type 2 diabetes mellitus. The six-month course of nebivolol decreased the MMP-9 level in patients with 
ischemic CHF after CABG, including patients with T2DM.
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Introduction
Chronic heart failure continues to be one of the most 
common severe cardiovascular diseases with unfavorable 
prognosis (Fomin 2016, Mareev et al. 2017). It is gene-
rally accepted that CHF and its severity correlate with 
a decreased systolic LV function, which is estimated by 
the value of the left ventricular ejection fraction (LVEF). 
CHF with reduced ejection fraction (HFrEF) is diagnosed 
when left ventricle myocardial contractility is less than 
40%. The most common CHF forms are HFpEF with 
LVEF over 50% and HFmrEF with LVEF from 40 to 49% 
(Rich et al. 2018). In recent years, much attention has 
been paid to studying HFmrEF, as its pathophysiology is 
poorly understood and its optimal treatment remains lar-
gely undetermined (Mohammed et al. 2012, Paulus and 
Tschöpe 2013, Upadhya et al. 2015).
Over the last decade, there have been active studies on 
the participation of LV diastolic dysfunction and DS in the 
progression of the heart failure (De Sutter et al. 2005, Lee 
et al. 2009). Ischemia and progressive interstitial fibrosis 
are assumed to be their development basis (Mohammed 
et al. 2015, Crendal et al. 2014). One of the potential bi-
omarkers of cardiac fibrosis is MMP-9 (Querejeta et al. 
2004, Zile et al. 2015). Its significant expression is as-
sociated with coronary arteritis (Choudhary et al. 2006, 
Tanindi et al. 2011), metabolic imbalance of extracellu-
lar matrix collagen and myocardial dysfunction (Gandhi 
et al. 2011). In this regard, the possibility of potency assay 
of MMP-9 to assess the antifibrotic activity of pharma-
cotherapy in patients with CHF of ischemic origin with 
preserved and midrange ejection fraction in the setting of 
revascularization is very promising and relevant.
Beta-blockers (β-blockers) are recommended as first-
line therapy (Osipova 2013, Belsey et al. 2015) in patients 
with CHF and coronary heart disease (CHD). However, the 
choice of drugs from the group of β-blockers in patients with 
myocardial dissynchrony and ischemic HFpEF or HFmrEF 
in the setting of revascularization remains an open question.
In recent years, the number of patients with T2DM has 
been rapidly increasing. T2DM is considered as an inde-
pendent risk factor for CHD and CHF progression (Rad-
chenko and Кoroliuk 2015, Dedov et al. 2015). In this 
regard, it is important to study the pleiotropic effects of 
nebivolol and bisoprolol on mechanical dissynchrony and 
collagen metabolism in patients with ischemic HFpEF or 
HFmrEF in the setting of the coronary revascularization 
and comorbid T2DM.
Objective of the study
To conduct a comparative analysis of the effect of long-
term pharmacotherapy with β-blockers (nebivolol and 
bisoprolol) on structural and functional remodeling, me-
chanical dissynchrony of the myocardium and the level 
of MMP-9 in patients with ischemic HFpEF or HFmrEF 
in the setting of myocardial revascularization via CABG.
Materials and methods
The study included 308 patients aged 52 to 72 years (mean 
age 62±6 years) who were treated in the Cardiac Surge-
ry Department of St. Ioasaph Belgorod Regional Clinical 
Hospital in the period from 2015 to 2018.
Entry criteria: 1) CHF FC I-II caused by coronary ar-
tery disease, obliterating atherosclerosis of coronary ar-
teries and myocardial revascularization performed via 
CABG; 2) LVEF>40%; 3) Compensated type 2 diabetes 
mellitus on the background of concomitant antihypergly-
cemic therapy; 4) Patient Informed Consent to participate 
in the study.
Exclusion criteria: CHF FC III-IV; LVEF<40%; con-
genital heart disorders and acquired valvular heart dis-
eases; myocarditis, pericarditis, cardiomyopathy, acute 
myocardial infarction; complicated postoperative period; 
comorbid acute inflammatory, infectious, oncologic, im-
mune complex diseases; stable intraventricular conduc-
tion abnormalities; acute renal failure and chronic kidney 
disease (plasma creatinine >2.5 mg/dL); and dissent of 
the patient.
The general group (308 patients with ischemic CHF FC 
I-II) consisted of 258 (83.8%) men and 50 (16.2 %) wom-
en aged 52 to 72 years (mean age 62±6 years). Table 1 pre-
sents the characteristics of patients included in the study.
Patients were divided into 3 groups by the stratifica-
tion randomization method. The clinical characteristics of 
the examined groups of patients are presented in Table 2. 
Group 1 consisted of 120 patients with ischemic CHF and 
EchoCG-confirmed mechanical DS; group 2 consisted 
of 120 patients with ischemic CHF without mechanical 
DS; group 3 consisted of patients with ischemic CHF, 
DS and comorbid T2DM. The study design is shown in 
Figure 1. All groups were further divided into subgroups 
according to the drug therapy with β-blocker (nebivolol 
and bisoprolol) using the random number table generated 
in STATISTICA. The study additionally evaluated a per-
Table 1. Clinical characteristic of the examined patients
Criteria Value
Total number of the examined patients, n (%) 308 (100%)
Men, n (%) 258 (83.8%)
Women, n (%) 50 (16%)
Age, years From 52 to 72
Meanage, years 62±6
CHF FC I, n (%) 159 (51.6%)
CHF FC II, n (%) 149 (48%)
LVEF 40–49 % n, (%) 109 (35.5%)
LVEF ˃50 %, n (%) 199 (64.5%)
QRS msec ˃120 msec, n (%) 58 (18.82%)
Previous myocardial infarction, n (%) 252 (82%)
Heart rhythm disorder, n (%) 77 (25%)
Ischemic mitral insufficiency up to degree 2, n (%) 107 (34.8%)
Type 2 diabetes mellitus, n (%) 68 (22%)
Note: CHF - chronic heart failure, FC - functional class, LVEF - left 
ventricular ejection fraction.
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sonalized approach to the β-blockers therapy in the sub-
groups of patients formed depending on the LVEF level: 
subgroups with midrange ejection fraction (40–50%) and 
with preserved ejection fraction (>50%).
Βeta-blockers were prescribed on the 2nd day after 
CABG. The initial dose of nebivolol (Nebilet, Berlin-Che-
mie AG, Germany) was 1.25–2.5 mg/day and that of biso-
prolol (Concor, Merck KGaA, Germany) – 1.25–2.5 mg/
day. The dose titration is presented in Table 3.
In the group of patients with ischemic CHF, DS and 
comorbid T2DM, the average daily dose of nebivolol 6 
months later was 5.25±2.37 mg/day; that of bisoprolol 
– 5.01±2.89 mg/day. For 6 months, the patients received 
optimal pharmacotherapy, including calcium antago-
Figure 1. Examination design of patients with ischemic CHF FC I–II with preserved left ventricular ejection fraction after myocar-
dial revascularization by CABG. Note: CABG – coronary artery bypass grafting, CHF – chronic heart failure, FC – functional class, 
DS – dyssynchrony, EF – ejection fraction, ECG – electrocardiography, EchoCG – echocardiography, MMP-9 – metalloproteinase 9
Table 2. Clinical characteristics of the examined groups of patients
Clinical data Group 1 With mechanical 
dyssynchrony
Group 2 Without 
mechanical dyssynchrony
Group 3 With T2DM and 
mechanical dyssynchrony
Total number of the examined patients, n (%) 120 (100 %) 120 (100 %) 68 (100%)
Men, n (%) 92 (78.9 %) 110 (91.6 %) 36 (52.2 %)
Women, n (%) 28 (23 %) 10 (8.3 %) 32 (47.8 %)
Mean age, years 62 ± 6.6 59 ± 5.1 63 ± 5.2
NYHA CHF FC I, n (%) 47 (37.5 %) 82 (65.8 %) 26 (38.8 %)
NYHA CHF FC II, n (%) 75 (62.5 %) 40 (33.3 %) 42 (61.2 %)
LVEF 40–49 %, n (%) 70 (58 %) 15 (12.5 %) 22 (32.4 %)
LVEF ˃ 50 %, n (%) 50 (41.6 %) 105 (87.5 %) 46 (67.6 %)
QRS msec ˃120 msec, n (%) 31 (25.5 %) 10 (6.66 %) 15 (22.3 %)
Previous myocardial infarction, n (%) 102 (84 %) 95 (79 %) 59 (86.4 %)
Heart rhythm disorder, n (%) 28 (23.7 %) 32 (26.6 %) 15 (22.8 %)
Ischemic mitral insufficiency up to degree 2, n (%) 59 (49 %) 22 (18.3 %) 27 (40.3 %)
Note: LVEF – left ventricular ejection fraction, NYHA – New York Heart Association, CHF – chronic heart failure, FC – functional class
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nists from the dihydropyridine group, angiotensin-con-
verting enzyme inhibitors (ACE inhibitors) or angioten-
sin II receptor blockers (ARB), statins, and antiplatelets. 
The patients were examined at three stages. The first ex-
amination was performed before CABG, the second one 
– on the 10th day and the third one – 6 months into the 
course of pharmacotherapy. Physical examination of 
the patient, ECG, EchoCG, blood sampling, detection 
of the MMP-9 level in blood plasma were carried out at 
the first stage (without β-blocker administration) and 6 
months into the course of pharmacotherapy. The MMP-
9 plasma level was measured at the Test Laboratory 
Center of the Federal State-Funded Healthcare Institu-
tion “Hygienic and Epidemiological Center in Belgorod 
region”, using enzyme immunoassay kit for measuring 
human MMP-9 (Bender MedSystems GmbH, Austria). 
The study was performed using an enzyme immuno-
assay photoelectric analyzer SANRIS, Austria. The 
quantitative parameters were calculated by constructing 
a calibration curve using computer software, with the 
amount expressed in ng/ml.
EchoCG was performed to assess the structures and 
functions of the heart chambers. Standard pulsed Doppler 
echocardiography was used to evaluate interventricular 
mechanical delay (IVMD). The assessment of the intra-
ventricular mechanical dissynchrony was performed by 
Tissue Doppler Imaging (Tissue Synchronization Imag-
ing, or TSI) using 6 basal and 6 midsegment models (Yu 
et al. 2005). For each range, the following TSI parame-
ters were calculated: septal lateral delay, septal posterior 
delay, and basal max delay. The time to peak myocardial 
systolic velocity in the ejection phase (TS) was measured 
with reference to the QRS complex. The maximum delay 
across all 12 segments (TS12) and TS standard deviation 
(TS-SD) of all 12 LV segments were calculated (Cazeau et 
al. 2003, Yu et al. 2003).
Statistical data processing was performed using Statis-
tica for Windows.The data are presented as median (Me) 
and interquartile ranges (25th and 75th percentile ranges). 
A normality of data distribution was assessed using the 
Kolmogorov-Smirnov test. For the dependent samples 
(treatment dynamics), there was used the signs test and 
the Wilcoxon test, with the preliminary Friedman test if 
the number of observation points in dynamics was more 
than 2, were used. The Mann-Whitney test was used for 
independent samples (distribution into subgroups by fea-
ture). Spearman’s rank correlation coefficient was used to 
study the relationship between the variants. Differences 
were considered significant when p<0.05.
Results and discussion
It was found that in patients with DS (in comparison with 
patients without DS) LV diastolic dimension (LVDD) 
increased by 9% (p<0.05), indexed left ventricular end 
systolic volume (ESVI) – by 8% (p<0.05), left atrium ca-
vity – by 6.5% (p<0.01), pulmonary artery systolic pres-
sure (PASP) – by 25% (p<0.01). LVEF decreased by 16% 
(p<0.001). Severe diastolic dysfunction of LV, which sho-
wed in an increase in E/E’ by 21% (p<0.05), DT – by 
17.6% (p<0.05), isovolumetric relaxation time (IVRT) by 
13% (p<0.05) and a decrease in E/A by 16% (p<0.01) and 
in E’ – by 19% (p<0.01), was determined (Table 4).
After revascularization, there was an improvement in 
myocardial dysynchrony indices. It was proved that in the 
early postoperative period after CABG in the DS group 
there was an improvement in myocardial synchronicity. 
Thus, TS12 decreased by 30% (p<0.01), TS-SD – by 28% 
(p<0.001), septal lateral delay – by 39% (p<0.001), septal 
posterior delay – by 31% (p<0.01), basal max delay – by 
36% (p<0.001), and IVMD – by 15% (p<0.05).
Synchronicity was restored, accompanied by an im-
provement in LV myocardial contractility by 8% (p<0.05) 
and LV lusitropy (an increase in E/A by 27% (p<0.01), a 
decrease in DT by 14% (p<0.01) and in E/E’ – by 15% 
(p<0.05)).
The study found that long-term administration of 
nebivolol in patients with DS decreased EDVI by 8% 
p<0.05), ESVI – by 13% (p<0.05), left ventricular mass 
index (LVMI) – by 12% (p<0.001), PASP – by 8% 
(p<0.01), increased LVEF by 10% (p<0.01) and E/A – by 
19% (p<0.05) and decreased DT by 12% (p <0.05), im-
proved myocardial synchronicity by reducing IVMD by 
15% (p<0.05), TS12 – by 28% (p<0.001), TS-SD – by 
31% (p <0.01), septal lateral delay – by 41% (p<0.001), 
septal posterior delay – by 39% (p<0.01), basal max delay 
– by 40% (p<0.01) (Table 5).
Long-term administration of bisoprolol showed a 
decrease in EDVI – by 12% (p<0.05), ESVI – by 17% 
(p<0.001), LVMI – by 14% (p<0.001), PASP – by 9% 
(p<0.01). LVEF increased by 8% (p<0.01), LV lusitropy 
improved by increasing E/A by 21% (p<0.01) and de-
creasing DT by 7% (p<0.05). There was also a decrease 
in TS12 by 22% (p<0.05), in TS-SD by 21% (p<0.05) and 
in basal max delay by 30% (p<0.05). It was found that 
in patients with DS, both nebivolol and bisoprolol had a 
positive effect on the structural and functional parameters 
and LV diastolic function. At the same time, there was 
Table 3. The average daily doses of β-blockers (Nebivolol, Bisoprolol) during titration for 6 months in patients with dyssynchrony
Drug Initial dose 7th day 
of the therapy
30th day 
of the therapy
3 months 
of the therapy
6 months 
of the therapy
examination examination interview physician visit, 
examination
physician visit, 
examination
Nebivolol, mg/day (n=56) 2.4±0.81 3.91±1.23 4.52±0.98 5.23±1.03 5.11±2.56
Bisoprolol, mg/day (n=64) 2.17±1.03 3.43±1.31 4.56±1.23 5.31±1.65 4.92±2.41
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Table 4. Structural and functional parameters in patients with ischemic chf depending on the presence of myocardial dyssynchrony 
me (Q1–Q3)
Parameters, units of 
measurement
Point of examination LV Dyssynchrony n = 120 Without LV dyssynchrony n = 120 р
LV EDVI, ml/m2 Before CABG 58.99 (51.48–66.48) 60.55 (54.41–68.75) ˃0.05
7th day of the therapy 57.99 (45.29–64.48) 57.79 (47.20–63.75) ˃0.05
р ˃0.05 ˃0.05 ˃0.05
LV ESVI, ml/m2 Before CABG 28.04 (20.87–36.35) 25.77 (19.67–32.73) ˂0.05
7th day of the therapy 25.31 (19.76–28.43) 24.39 (18.72–31.23) ˃0.05
р ˂0.05 ˃0.05 <0.05
LVEF,% Before CABG 48.50 (45.00–54.00) 59.00 (54.50–60.00) ˂0.001
7th day of the therapy 53.50 (48.00–55.00) 57.50 (55.00–60.00) ˂0.001
р ˂0.05 ˃0.05 <0.05
Е’, msec Before CABG 0.05 (0.04–0.06) 0.06 (0.06–0.07) ˂0.01
7th day of the therapy 0.06 (0.05–0.07) 0.06 (0.06–0.07) ˃0.05
р ˃0.05 ˃0.05 ˃0.05
Е/А Before CABG 0.76 (0.64–0.83) 0.82 (0.66–0.96) <0.01
7th day of the therapy 0.94 (0.77–1.33) 0.96 (0.94–1.44) <0.05
р <0.01 ˃0.05 <0.05
E/E’ Before CABG 10.50 (7.44–16.10) 9.20 (7.15–10.42) ˂0.05
7th day of the therapy 10.00 (6.77–13.40) 8.20 (7.52–10.65) ˂0.05
р <0.05 ˃0.05 ˃0.05
DT, msec Before CABG 224.00 (198.0–275.0) 97.00 (89.00–110.50) ˂0.05
7th day of the therapy 207.00 (184.00–231.00) 202.50 (181.50–211.50) ˃0.05
р <0.01 ˃0.05 ˂0.05
Note: LV – left ventricle, EDVI – indexed left ventricular end diastolic volume, ESVI – indexed left ventricular end systolic volume, LVEF – left 
ventricular ejection fraction, E – early diastolic tissue velocity, Е’ – peak early diastolic mitral annular velocity, DT – deceleration time, A – Peak 
late diastolic velocities
Table 5. The comparative analysis of the effect of the 6-month course of Nebivolol (5.1±2.6 mg/day) and Bisoprolol (4.9±2.4 mg/
day) on the structural and functional parameters and dyssynchrony in patients with ischemic chf in the group with myocardial dys-
synchrony. Me (Q1–Q3)
Parameters, units of 
measurement
Nebivolol, n=56 Bisoprolol, n=64 p
Before CABG 6 months of the therapy Before CABG After 6 months of the 
therapy
1 2 3 4 1–2/3–4
LV EDVI, ml/m2 61.00   (51.0–78.0-) 59.41*  (50.40–67.00) 55.11  (47.00–69.00) 57.40*  (45.92–61.53) >0.05
LV ESVI ml/m2 30.00  (22.82–39.21) 26.91*  (22.40–32.72) 26.93  (19.83–34.22) 23.50**  (16.40–30.71) >0.05
LVEF, % 48.00  (45.00–57.00) 53.00**  (51.00–62.00) 49.00  (46.00–55.00) 54.05**  (50.00–60.00) >0.05
LVMI, g/m 132.11  (112.00–157.20) 117.1***  (102.05–125.34) 123.13  (118.00–141.21) 106.00**  (96.00–119.31) >0.05
PASP, mm Hg 40.00  (38.00–45.00) 36.0**  (32.00–40.00) 38.0  (35.00–45.00) 34.0**  (31.00–40.00) >0.05
E/A 0.8  (0.62–1.1) 0.96*  0.96(0.72–1.2) 0.76  (0.64–0.83) 0.83**  (0.74–0.98) >0.05
DT, msec 222.00  (197.0–275.0) 204.00*  (132.00–271.00) 234.00  (195.00–272.00) 233.00*  (181.00–246.00) >0.05
TS12, msec 155.00  (124.00–177.00) 108.00***  (89.00–140.00) 146.00  (119.00–183.00) 115.00*  (100.00–160.00) >0.05
TS-SD 50.00  (41.00–65.00) 35.0 **  (28.00–51.00) 45.00  (40.00–65.00) 38.00  (31.00–62.00) ˂0.05
Septal lateral delay, 
msec
91.00  (77.00–120.00) 48.0 ***  (20.00–78.00) 92.00  (28.00–129.00) 64.00  (38.00–101.00) ˂0.05
Septal posterior delay, 
msec
78.00  (48.00–119.00) 37.00**  (21.00–58.00) 56.00  (48.00–96.00) 41.00  (21.00–79.00) ˂0.05
Basal max delay, 
msec
126.00  (101.00–154.00) 73.00**  (47.00–125.00) 126.00  (106.00–135.00) 77.00*  (56.00–117.00) >0.05
IVMD 19.00  (14.0–026.00) 16.00*  (10.00–22.00) 18.00  (12.00–22.00) 16.00  (15.00–22.00) >0.05
Note: *p<0.05, ** p<0.01, *** p<0.001 in comparison with values before CABG, LV – left ventricle, EDVI – indexed left ventricular end diastolic 
volume, ESVI – indexed left ventricular end systolic volume, LVEF – left ventricular ejection fraction, E – early diastolic tissue velocity, Е’ – peak 
early diastolic mitral annular velocity, DT – deceleration time, A – Peak late diastolic velocities, PASP – pulmonary artery systolic pressure, TS12 – 
all segments max delay, TS-SD – all segments standard deviation, IVMD – inter-ventricular mechanical delay
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no significant difference in the effect of these drugs. A 
comparative analysis of the effect of long-term therapy 
with nebivolol and bisoprolol on DS revealed statistically 
significant differences in favor of nebivolol (Table 6). In 
patients with HFmrEF and DS, there was an increase in 
LVEF both in case of administering nebivolol (by 18%, 
p<0.01) and bisoprolol (by 10%, p<0.05). Improvement 
of LV diastolic function was noted in patients with HFm-
rEF taking nebivolol (an increase in E/A by 25%, p<0.05, 
and in DT by 22%, p<0.05). In patients taking bisopro-
lol with HFmrEF and HFpEF, LV diastolic dysfunction 
improved in the same way (an increase in the E/A ratio 
was 21% (p<0.05) and DT by 18.7% (p<0.05), respec-
tively). Long-term administration of nebivolol had a pos-
itive effect on the DS progression mainly in patients with 
HFpEF, which was confirmed by a decrease in TS12 by 
30% (p<0.001), TS-SD –by 32% (p<0.01), septal lateral 
delay – by 56% (p<0.001), septal posterior delay –by 54% 
(p<0.01), basal max delay – by 51% (p<0.01) and was not 
determined in patients taking bisoprolol (Table 7).
It was found that in patients without DS after the 
6-month pharmacotherapy, the effect of nebivolol showed 
in a decrease in LVDD by 19% (p <0.01), EDVI – by 
17% (p<0.05), PASP – by 9% (p<0.05) and an increase in 
LVEF by 9% (p <0.05). The positive effect of nebivolol 
on LV diastolic function was proved, which was showed 
in an increase in E/A by 19% (p<0.01), E` – by 16% 
(p<0.05), a decrease in E/E’ by 9.8% (p<0.05) and DT – 
by 12% (p<0.05), and which indicates an improvement in 
LV lusitropy and LV filling pressure (Table 8).
The administration of bisoprolol (6 months) showed an 
effect on the reduction of EDVI by 18% (p<0.05), ESVI – 
by 25% (p<0.01), PASP – by 9% (p<0.01) and an increase 
in LVEF by 7% (p<0.05), while the effect on the LV dias-
tolic function was not determined.
In patients with HFmrEF without DS taking nebivolol, 
increased LV lusitropy was more marked compared with 
patients with HFpEF, (increase in E/A by 24% (p<0.05), 
decrease in E/E’ by 6% (p<0.05) and DT – by 11% 
(p<0.05). The dynamics of LV diastolic function in pa-
tients with HFmrEF and HFpEF taking bisoprolol was the 
same and had no statistical significance. A significant in-
crease in LVEF in patients with HFmrEF without myocar-
dial dyssynchrony was revealed both when administering 
nebivolol (10%, p<0.05) and bisoprolol (17%, p<0.05), 
whereas patients with HFpEF had no significant increase 
in the LV contractility.
It was found that T2DM was accompanied by an in-
crease in E/A by 11.8% (p<0.05), E/E’ – by 16% (p 
<0.05), DT – by 13.2% (p>0.05), and IVRT – by 8.6% 
(p>0.05). The indicators of intra-LV dyssynchrony were 
extended – TS12 by 9.7% (p<0.05), TS-SD by 13,8% 
(p<0.05), septal lateral delay by 21% (p<0.05), basal 
maximum delay by 10% (p<0.05); IVMD increased by 
21% (p<0.05) (Table 9).
It was determined that the administration of nebivolol 
(6 months) reduced ESVI by 15% (p<0.05), PASP – by 
15% (p<0.01) and LVMI – by 12% (p<0.01), whereas in-
creased LVEF by 10% (p<0.05). There was no significant 
effect on LV diastolic function. At the same time, the in-
fluence on the DS was determined. For example, TS12 
decreased by 37% (p<0.01), TS-SD – by 29% (p<0.05), 
and septal lateral delay –by 53% (p<0.01) (Table 10).
When taking bisoprolol (6 months), there was a de-
crease in EDVI by 18% (p<0.05), ESVI – by 20% 
(p<0.01), LVMI – by 11% (p <0.05); LVEF grew by 11% 
(p<0.01). After 6 months of bisoprolol therapy, the dy-
namics of diastolic function and DS was not statistically 
significant. Long-term administration of both nebivolol 
and bisoprolol in patients with HFmrEF and HFpEF with 
comorbid T2DM was not found to improve LV diastolic 
function, which is probably due to the pronounced pro-
cesses of fibrous degeneration and progressive subclini-
cal LV diastolic dysfunction in this category of patients.
It was proved that in patients with HFpEF with comor-
bid T2DM nebivolol reduced TS12 by 37% (p<0.01), TS-
SD – by 29% (p<0.05), and septal lateral delay – by 53% 
(p<0.01) (Table 11). In patients with HFpEF and HFmrEF 
with comorbid T2DM taking bisoprolol, no decrease in 
dyssynchrony parameters was revealed.
In the study of the fibrosis marker, the MMP-9 level 
in the blood plasma of patients with ischemic CHF of the 
general group was found to be 4.7 times higher than that 
in the control group (p<0.001) (Fig. 2). The concentration 
of MMP-9 in the group of patients with DS was signif-
icantly higher – by 14% (p<0.05) than in patients with-
out DS (Fig. 3). Comorbid T2DM significantly increased 
MMP-9 level – by 12% (p<0.01) (Fig. 4).
In patients with ischemic CHF before treatment, 
the correlation between MMP-9 level in blood plasma 
and the severity of CHF FC (p<0.05) was determined. 
Correlation between MMP-9 level and EDVI (r=0.27, 
p<0.01), ESVI (r=0.43, p<0,01), LVMI (r=0.60, 
p<0.001), LVEF (r=-0.60, p<0.001), parameters of the 
LV diastolic function: E`1 (r=-0.58, p<0.001), E/A (r=-
0.49, p<0.001), DT (r=0.43, p<0.001), IVRT (r=0.50, 
p<0.0001)), as well as indicators of intra-LV dyssyn-
chrony: TS12 (r=0.54, p<0.001), TS-SD (r=0.49, 
Table 6. The Comparative analysis of the effect of long-term 
therapy (6 months) with Nebivolol and Bisoprolol on myocar-
dial dyssynchrony in patients with ischemic chf in the setting of 
revascularization. Me (Q1–Q3)
Parameters, units of 
measurement
Nebivolol, 
%
Bisoprolol, 
%
Dynamics, 
%
p
1 2 1–2 1–2
TS12, msec 28.29 20.51 7.78 >0.05
TS-SD 31.11 18.31 12.8 ˂0.05
Septal lateral delay, msec 41.02 25.97 15.5 ˂0.05
Septal posterior delay, msec 39.84 30.19 9.65 ˂0.05
Basal max delay, msec 42.35 34.28 8.93 >0.05
APEI, msec -7.14 -8.25 -1.11 >0.05
IVМD -6.66 2.01 4.65 >0.05
Note: TS12 – all segments max delay, TS-SD – all segments 
standard deviation, IVMD – inter-ventricular mechanical delay, 
APEI – Aortic Pre-Ejection Period.
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Table 7. The Effect of 6-months therapy with Nebivolol (5.1±2.6 mg/day) on myocardial dyssynchrony in patients with ischemic 
chf depending on lvef. Me (Q1–Q3)
Parameters, units 
of measuremen
HFmrEF n=20 HFpEF, n=36
p
Before CABG After 6 months of therapy Before CABG
After 6 months of 
therapy
1 2 3 4 1–2 3–4 1–2/3–4
TS12, msec 155.00 (125.00–190.0) 139.00 (91.00–147.00) 160.00 (123.00–176.0) 98.50 (84.50–117.50) <0.05 <0.05 >0.05
TS-SD 50.00 (44.00–69.00) 36.00 (29.00–55.00) 52.00 (39.00–64.00) 32.47 (12.63–49.77) <0.05 <0.01 >0.05
Septal lateral delay, 
msec 91.00 (77.00–143.00) 48.00 (19.00–79.00) 91.00 (71.00–113.00) 40.00 (24.00–76.00) >0.05 <0.05 <0.05
Septal posterior 
delay, msec
96.00 (48.00–126.00) 56.00 (21.00–64.00) 72.00 (48.00–111.00) 36.00 (20.00–43.00) >0.05 <0.05 <0.05
Note: TS12 – all segments max delay, TS-SD – all segments standard deviation, HFmrEF – chronic heart failure with midrange ejection fraction, 
HFpEF – chronic heart failure with preserved ejection fraction.
Table 8. The comparative analysis of the effect of long-term therapy with Nebivolol (5.4±1.7 mg/day) and Bisoprolol (4.5±1.6 mg/
day) in patients with ischemic chf in the setting of revascularization in the group without myocardial dyssynchrony. Me (Q1–Q3)
Parameters, units of 
measurement
Nebivolol, n=61 Bisoprolol, n=59 p
Before CABG After 6 months of the 
therapy
Before CABG After 6 months of the 
therapy
1 2 3 4 1–2/3–4
EDVI, ml/m2 55.96  
(50.50–66.21)
51.66*  
(42.05–61.72)
61.15  
(56.00–67.00)
49.42*  
(41.91–58.55)
>0.05
ESVI, ml/m2 22.7  
(18.21–28.63)
17.2  
(14.45–28.33)
25.9  
(22.81–29.24)
16.5**  
(13.44–23.72)
>0.05
LVEF, % 58.00  
(55.00–60.00)
61.00*  
61.00(57.00–64.0)
58.0  
(50.00–60.00)
60.0*  
60.00(55.00–54.00)
>0.05
PASP, mm Hg 34.0  
(30.0–35.0)
30.0*  
30.0(28.0–34.0)
32.0  
(30.0–36.0)
28.0**  
28.0(27.0–32.0)
>0.05
E/A 0.8  
(0.62–0.90)
1.2**  
(0.91–1.00)
0.8  
(0.65–0.91)
0.9  
(0.65–1.23)
˂0.05
E/E’ 9.22  
(7.10–10.40)
8.30*  
8.3(7.10–9.40)
9.42  
(8.48–12.30)
9.35  
(6.41–12.00)
>0.05
Note: * p<0.05, ** p<0.01, *** p<0.001 in comparison with values before CABG, EDVI – indexed left ventricular end diastolic volume, ESVI – 
indexed left ventricular end systolic volume, LVEF – left ventricular ejection fraction, PASP – pulmonary artery systolic pressure, A – Peak late 
diastolic velocities, E – early diastolic tissue velocity, Е’ – peak early diastolic mitral annular velocity
Table 9. Structural and functional parameters in patients with 
ischemic CHF with comorbid T2DM and myocardial dyssyn-
chrony before revascularization. Me (Q1–Q3)
Parameters CHF with DS and DM2, n=68
CHF with DS and 
without DM2, n=120
E/A 0.67 (0.62–0.79) * 0.76 (0.64–0.83)
E/E’ 12.50 (9.84–19.8) * 10.50 (7.44–16.10)
DT, msec 228.00(197.00–286.00) 220.00(196.00–246.00)
IVRT, msec 115.00(98.00–126.00) 104.00(90.00–116.00)
IVMD 19.00(14.00–23.00)* 15.00(12.00–22.00)
TS12, msec 175.00 (139.00–198.00)* 158.00 (129.00–187.00)
TS-SD 58.00 (38.00–78.00)* 52.00 (36.00–68.00)
Septal lateral 
delay, msec 115.00 (49.00–142.00)** 91.50 (53.50–114.00)
Septal posterior 
delay, msec 48.53(26.00–72.00) 68.5 (40.00–115.00)
Basal max 
delay, msec 138.00 (98.00–174.00) * 124.00 (103.00–144.00)
Note: * p<0.05, ** p<0.01 in comparison with patients without T2DM, 
E – early diastolic tissue velocity, Е’ – peak early diastolic mitral annular 
velocity, DT – deceleration time, A – Peak late diastolic velocities, TS12 – 
all segments max delay, TS-SD – all segments standard deviation, IVRT – 
isovolumetric relaxation time, IVMD – inter-ventricular mechanical delay.
Figure 2. ММР-9 levels in the blood plasma of the general group 
of patients before revascularization (p<0.001); 0 – reference 
range, 1– patients with ischemic CHF (n=188). Note: MMP-9 – 
metalloproteinase 9, CHF – chronic heart failure
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Figure 4. Distribution of ММР-9 levels in the blood plasma of 
patients with CHF, DS and T2DM and patients with CHF, DS 
without T2DM (p<0.01); 0 – the group without T2DM (n=62), 
1– the group with T2DM (n=68). Note: MMP-9 – metallopro-
teinase 9, CHF – chronic heart failure, DS – dyssynchrony, 
T2DM – type 2 diabetes mellitus.
Figure 3. Distribution of ММР-9 levels in the blood plasma of 
patients with ischemic CHF (p<0.05); 0 – the group without DS 
(n=58), 1– the group with DS (n=62). Note: MMP-9 – metallo-
proteinase 9, CHF – chronic heart failure.
Table 10. The comparative analysis of the effect of Nebivolol (5.3±2.4 mg/day) and Bisoprolol (5.0±2.9 mg/day) on Structural and 
Functional parameters and myocardial dyssynchrony in patients with ischemic CHF and comorbid T2DM. Me (Q1–Q3)
Parameters, units of 
measurement
Nebivolol, n=36 Bisoprolol, n=32 p
Before CABG After 6 months of the 
therapy
Before CABG After 6 months of the 
therapy
1 2 3 4 1–2/3–4
LV EDVI, ml/m2 62.20 (59.40–77.21) 55.51 (55.3–64.4) 58.9 (46.7–76.1) 48.32 41.11–63.92)* >0.05
LV ESVI, ml/m2 26.10 (23.8–38.9) 22.72 (20.0–28.3)* 25.0 0 (19.4–31.1) 20.00 (16.1–23.9)** >0.05
LVEF, % 56.00 45.00–59.00) 62.00* (52.00–64.00) 55.00 (46.00–60.00) 57.00* (55.0–65.00) >0.05
LVMI, g/m2 112.89 (103.18–141.33) 101.16** (91.34–121.20) 124.13 (114.00–141.20) 106.57** (105.00–128.32) >0.05
PASP, mm Hg 40.00 (37.00–45.00) 34.00** (30.00–40.00) 37.00 (34.00–45.00) 34.00 (32.00–40.00) ˂0.05
E/E’ 7.40 (6.04–15.90) 9.25 (8.51–15.74) 10.51 (10.20–13.10) 14.40 (10.40–16.60) >0.05
E/A 0.86 (0.62–1.15) 0.97 (0.71–1.21) 0.78 (0.63–0.81) 0.84 (0.81–0.86) >0.05
TS12, msec 174.00 (109.00–182.00) 98.50** (63.00–135.00) 136.00 (107.00–176.00) 115.0 (51.00–170.00) >0.05
TS-SD 55.00 (32.00–63.00) 32.50 * (17.50–47.00) 44.00 (36.00–64.00) 38.00 (19.00–63.00) ˂0.001
Septal lateral delay, msec 91.00 (77.00–120.00) 48.00** (20.00–78.00) 92.00 (19.00–128.00) 64.0 (42.00–106.00) ˂0.001
Basal max delay, msec 92.00 (43.00–126.00) 82.00 (38.00–125.00) 110.00 (104.00–147.00) 78.00 (58.00–119.00) >0.05
Note: * p <0.05, ** p <0.01, *** p <0.001 in comparison with values before CABG, E – early diastolic tissue velocity, Е’ – peak early diastolic 
mitral annular velocity, DT – deceleration time, A – Peak late diastolic velocities, TS12 – all segments max delay, TS-SD – all segments standard 
deviation, LV – left ventricle, EDVI – indexed left ventricular end diastolic volume ESVI – indexed left ventricular end systolic volume, LVEF – left 
ventricular ejection fraction, PASP – pulmonary artery systolic pressure
p<0,001), septal lateral delay (r=0.44, p<0.001), and 
septal posterior delay (r=0.37, p<0.001) and IVMD 
(r=0.32, p<0.001) was observed. In patients with co-
morbid T2DM before treatment, MMP-9 level in the 
blood plasma correlated with LVEF (r=-0.43, p<0.05), 
LVMI (r=0.28, p<0.05) and LV volumes (EDVI (r=0.65, 
p<0.01), ESVI (r=0.57, p<0.01), E` (r=-0.64, p<0.01), 
E/A (r=-0.59, p<0.01), TS-SD (r=0.69, p<0,05), septal 
lateral delay (r=0.56, p<0.01)).
As a result of pharmacotherapy with nebivolol (6 
months) in patients with ischemic CHF of the gener-
al group in the setting of revascularization, there was a 
significant decrease in the MMP-9 level in blood plasma 
– by 11% (p<0.01) (Fig. 5), while in the patients of the bi-
soprolol group, there was an increase in the MMP-9 level 
in blood plasma by 6.5% (p>0.05) (Fig. 6).
At the same time, the dynamics of lowering of the 
MMP-9 level in blood plasma in patients treated with 
nebivolol is significantly higher than in patients treat-
ed with bisoprolol (p<0.01) (Table 12). Neither was a 
dose-dependent effect on reducing the MMP-9 level ob-
served in nebivolol.
After 6 months of nebivolol therapy, a decrease in the 
MMP-9 level by 7% in the group of patients with DS 
(p<0.05) and by 3% (p>0.05) in the group of patients 
without DS was observed (Table 13). There was also a 
statistically significant, though low, positive correlation 
between the MMP-9 level and a parameter of intra-LV 
dyssynchrony – TS12 (r=0.23, p<0.05).
As a result of pharmacotherapy with nebivolol (6 
months of administration) in patients with ischemic 
CHF, T2DM and DS, a significant 13% (p<0.05) de-
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Table 11. The effect of 6 months taking Nebivolol (5.3±2.4 mg/day) on LV diastolic function and myocardial dyssynchrony in pa-
tients with ischemic CHF and comorbid T2DM depending on the LV ejection fraction. Me (Q1–Q3)
Parameters, units of 
measurement
HFmrEF, n=15 HFpEF, n=21 p
Before CAB After 6 months of 
therapy
Before CABG After 6 months of 
therapy
1 2 3 4 1–2/3–4
E/A 0.81 (0.54–0.98) 0.83 (0.65–1.04) 0.81 (0.62–1.02) 0.76 (0.67–1.21) >0.05
E/E’ 15.70 (6.4–16.10) 16.0 (15.3–18.6) 7.4 (5.8–14.30) 8.8 (8.3–9.3) >0.05
TS12,
msec
173.00 (140.00–255.0) 166.00 (130.00–
170.00)
175.00 (89.00–177.0) 79.00** (52.00–
107.00)
˂0.05
TS-SD 50.00 (46.00–62.00) 60.00 (36.00–64.00) 60.00 (24.00–65.00) 28.00 ** (17.00–42.00) ˂0.05
Septal lateral delay, msec 77.00 (67.00–103.00) 20.00* (12.00–116.00) 84.00 (31.00–107.00) 20.00* (10.00–32.00) >0.05
Note: * p<0.05, ** p<0.01, in comparison with values before CABG, E – early diastolic tissue velocity, Е’ – peak early diastolic mitral annular 
velocity, DT – deceleration time, A – Peak late diastolic velocities, TS12 – all segments max delay, TS-SD – all segments standard deviation
Table 12. The effect of long-term therapy with Nebivolol (5.46±2.1 mg/day) and Bbisoprolol (5.1±1.9 mg/day) on the dynamics of 
MMP-9 level in patients with ischemic CHF in the setting of CABG. Me (Q1–Q3)
Parameters, units of 
measurement
Nebivolol (n=96) Bisoprolol (n=92) p
Before CABG After 6 months of the 
therapy
Before CABG After 6 months of the 
therapy
1 2 3 4 1–2/3–4
ММР-9 ng/ml 171.1 (150.2–190.5) 149.8 (142.1–163.1)** 165.4 (150.2–178.1) 167.7 (155.3–173.3) ˂0.01
Note: **р˂0.01 – significant differences in the group of nebivolol after 6 months of the therapy, CABG – coronary artery bypass grafting.
Figure 6. Dynamics of a decrease in MMP-9 level in the 
blood plasma of patients with ischemic CHF in the setting 
of revascularization within 6 months of bisoprolol therapy 
(р˃0.05) (n=92). Note: MMP-9 – metalloproteinase 9, CHF 
– chronic heart failure, DS – dyssynchrony, T2DM – type 2 
diabetes mellitus
Figure 5. Dynamics of an decrease in MMP-9 level in the blood 
plasma of patients with ischemic CHF in the setting of revascu-
larization within 6 months of nebivolol therapy (р˂0.01) (n=96). 
Note: MMP-9 – metalloproteinase 9, CHF – chronic heart fail-
ure, DS – dyssynchrony, T2DM – type 2 diabetes mellitus
Table 13. The effect of 6-month therapy with Nebivolol on the MMP-9 level in the groups of patients with DS and without DS. Me 
(Q1–Q3)
Parameters, units of measurement
Group DS (n=32) Group without DS (n=28) p
1 2 1–2
MMP-9, ng/ml
Before CABG 171.0 (160.0–185.1) 158.8 (120.0–173.1) <0.05
After 6 months of therapy 160.5 (144.7–172.1) 154.7 (138.9–169.7) >0.05
p ˂0.05 ˃0.05 <0.05
Note: **р˂0.01 – significant differences in the group of nebivolol after 6 months of the therapy, CABG – coronary artery bypass grafting, DS – dys-
synchrony, MMP-9 – metalloproteinase 9
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Figure 7. The reduction dynamics of the MMP-9 level during 
6-month therapy with nebivolol in patients with ischemic CHF 
and comorbid T2DM and DS (р˂0.05) (n=36). Note: MMP-9 – 
metalloproteinase 9, CHF – chronic heart failure, DS – dyssyn-
chrony, T2DM – type 2 diabetes mellitus
Figure 8. The comparison of reduction dynamics of the MMP-9 
level in the nebivolol (n=36) and bisoprolol (n=32) groups in pa-
tients with ischemic CHF and comorbid T2DM and DS (р˂0.01). 
Note: MMP-9 – metalloproteinase 9, CHF – chronic heart fail-
ure, DS – dyssynchrony, T2DM – type 2 diabetes mellitus
crease in the MMP-9 level in blood plasma was observed 
(Fig. 7), which was not observed in patients taking bi-
soprolol – dynamics decreased by 3% (p<0.05). At the 
same time, the reduction dynamics of the MMP-9 level 
in blood plasma of patients treated with nebivolol was 
significantly higher in comparison with that in patients 
treated with bisoprolol (p<0.01) (Fig. 8). Neither was a 
dose-dependent effect on reducing the MMP-9 level ob-
served in nebivolol.
Thus, our study proved that nebivolol has a pleiotrop-
ic effect of inhibiting the MMP-9 level, by influencing 
the alternative pathway of independent synthesis of an-
giotensin II by chemases. As a result, nebivolol has an 
antifibrotic effect.
Resume
As of today, there have not been wnough studies ai-
med at examining pharmacotherapy for patients with 
ischemic HFmrEF and HFpEF after CABG, including 
in combination with type 2 DM. When analyzing medi-
cal literature, some sporadic papers were found, which 
described experimental preclinical studies that proved a 
positive effect of β-blockers on LV diastolic dysfunction 
in heart failure by reducing the degree of myocardial fi-
brosis. X. Zhou et al. (2010) showed that nebivolol had 
improved diastolic relaxation and slowed LV remode-
ling by reducing interstitial fibrosis in insulin-resistant 
rats by activating endothelial NO synthase, reducing 
free radical concentrations of reactive oxygen species 
(ROS) and oxidative stress. The study by Y. Fang et al. 
(2011) demonstrated a more pronounced, when compa-
red to metoprolol, ability of nebivolol to improve LV 
hemodynamics and LV diastolic function by activating 
endothelial NO synthase, increasing NO bioavailabili-
ty and improving coronary vasorelaxation. L. Ma and 
co-authors in their study (in the transgenic rat model) 
confirmed the ability of a β-blocker nebivolol to improve 
diastolic function and to slow down the process of LV re-
modeling, reducing interstitial fibrosis by reducing myo-
cardial oxidative stress (Ma et al. 2012). However, there 
have been no studies aimed at investigating either the 
effect of long-term pharmacotherapy with nebivolol on 
cardiac dyssynchrony, LV diastolic function, or on the 
violation of collagen metabolism by suppressing MMP-
9 in patients with ischemic HFmrEF and HFpEF in the 
setting of myocardial revascularization.
The present study for the first time proved the effec-
tacy of long-term administration of β-blocker nebivolol 
to treat dyssynchrony in patients with ischemic HFpEF 
in the setting of revascularization. Besides, the study 
proved a positive impact of nebivolol on LV remodeling 
and diastolic function predominantly in patients with is-
chemic HFmrEF in the setting of revascularization with-
out myocardial DS. While conducting the study, the fea-
sibility of a personalized approach to pharmacotherapy 
in patients with comorbid T2DM was justified, and for 
the first time it was discovered that a pharmacotherapy 
with β-blocker nebivolol influenced the course of DS in 
such patients.
An important finding was a proven effect of long-
term administration of nebivolol on the reduction of 
the MMP-9 level in patients with ischemic CHF in the 
setting of revascularization, including patients with co-
morbid type 2 diabetes mellitus. The experimental data 
obtained during the study allow considering MMP-9 
as a biomarker of cardiac remodeling and DS. MMP-9 
is also an additional criterion confirming the presence 
of myocardial fibrosis and can be used as a pharmaco-
logical target in the treatment of patients with CHF and 
CHD, including patients with comorbid type 2 diabetes 
mellitus in the early and advanced time after myocardial 
revascularization.
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Conclusion
1. In patients with ischemic chronic heart failure, the 
presence of myocardial dyssynchrony is a predictor of 
deterioration in the CHF progression and manifests in 
impaired structural (left ventricular and left atrial en-
largement and expansion), hemodynamic (pulmonary 
hypertension) and functional (decrease in contractility 
and severe diastolic dysfunction of the left ventricle) 
heart parameters. The prognostic value of metallopro-
teinase-9 for cardiac dyssynchrony and the severity of 
chronic heart failure was proved.
2. The administration of nebivolol for 6 months according 
to the titrating regimen at the average dose of 5.1±2.6 
mg/day results in the restoration of myocardial syn-
chronicity in patients with ischemic chronic heart fail-
ure in the setting of revascularization, to a greater extent 
– in patients with preserved ejection fraction, which is 
confirmed by decreased intraventricular dyssynchro-
ny: TS-SD dissynchrony index decreased by 32%, 
TS12 maximum delay – by 30%, septal lateral delay 
– by 56%, septal posterior delay – by 54% and basal 
maximum delay – by 51%. After 6 months of thera-
py, nebivolol reduces the metalloproteinase-9 level in 
blood plasma by 11% (p<0.01) in patients of the general 
group and by 7% (p<0.05) in patients with dyssynchro-
ny, which is not observed in patients taking bisoprolol.
3. Six-month administration of nebivolol according to the ti-
trating regimen at the average dose of 5.4±1.7 mg/day im-
proves the left ventricle diastolic function in patients with 
ischemic chronic heart failure in the setting of revasculari-
zation without myocardial dyssynchrony, to a greater extent 
– in patients with midrange ejection fraction, which is con-
firmed by an increase in the E/A ratio by 24% (p<0.05), a 
decrease in E/E’ by 6% (p<0.05) and DT – by 11% (p<0.05), 
which is not observed in patients taking bisoprolol.
4. Patients with ischemic chronic heart failure and co-
morbid type 2 diabetes mellitus had severe LV diastol-
ic dysfunction, severe myocardial dyssynchrony and 
high levels of metalloproteinase-9.
5. Long-term administration (6 months) of nebivolol and 
bisoprolol has no effect on the course of left ventricular 
diastolic dysfunction in patients with ischemic chron-
ic heart failure in the setting of myocardial revascu-
larization with comorbid type 2 diabetes mellitus and 
myocardial dyssynchrony. Administration of nebivolol 
for 6 months at the average dose of 5.3±2.4 mg/day im-
proves intraventricular synchronicity in patients with 
chronic heart failure with preserved ejection fraction 
in the setting of revascularization in combination with 
type 2 diabetes mellitus, reducing the level of metallo-
proteinase-9 in blood plasma by 13% (p<0.05).
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FC – functional class
HFmrEF – chronic heart failure with midrange ejection 
fraction
HFpEF – chronic heart failure with preserved ejecti-
on fraction
HFrEF – chronic heart failure with reduced ejection fraction
Intra-LV dyssynchrony – intra-ventricular mechanical 
dyssynchrony
IVMD – inter-ventricular mechanical delay
IVRT – isovolumetric relaxation time
LAD – left atrial diameter
LV – left ventricle
LVDD – LV diastolic dimension
LVEF – left ventricular ejection fraction
MMP-9 – metalloproteinase 9
PASP – pulmonary artery systolic pressure
T2DM – type 2 diabetes mellitus
TDI – tissue Doppler imaging
TS12 – all segments max delay
TSI – Tissue Synchronization Imaging
TS-SD – all segments standard deviation
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